INTRA-CELLULAR THERAPIES INC (ITCI) Stock Price, Quote, News and Overview
NASDAQ:ITCI - Nasdaq - US46116X1019 - Common Stock - Currency: USD
ITCI Quote, Performance and Key Statistics
INTRA-CELLULAR THERAPIES INC
NASDAQ:ITCI (2/4/2025, 8:00:02 PM)
After market: 127.1 +0.2 (+0.16%)126.9
-0.29 (-0.23%)
The current stock price of ITCI is 126.9 USD. In the past month the price increased by 51.58%. In the past year, price increased by 74.39%.
ITCI Latest News, Press Releases and Analysis
The trading volume of these stocks is deviating from the norm in today's session.
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Unusual volume stocks in Friday's session
Discover the stocks with unexpected trading volume in today's session on the US markets.
These stocks have an unusual volume in today's session
In today's session, these stocks are experiencing unusual volume.
Unusual volume stocks in Wednesday's session
Unusual volume stocks are being observed in Wednesday's session.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders
ITCI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 81.23 | 784.20B | ||
| JNJ | JOHNSON & JOHNSON | 15.36 | 369.55B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.01 | 366.85B | ||
| MRK | MERCK & CO. INC. | 11.88 | 229.54B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.1 | 213.85B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.32 | 210.86B | ||
| PFE | PFIZER INC | 8.32 | 146.61B | ||
| SNY | SANOFI-ADR | 13.51 | 134.13B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.53 | 119.91B | ||
| ZTS | ZOETIS INC | 29.9 | 77.71B | ||
| GSK | GSK PLC-SPON ADR | 8.42 | 71.08B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.98 | 42.23B |
Related stock screener links
About ITCI
Company Profile
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 610 full-time employees. The company went IPO on 2014-01-31. The firm leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Company Info
INTRA-CELLULAR THERAPIES INC
135 Route 202/206, Suite 6
Bedminster NEW JERSEY 10016 US
CEO: Sharon Mates
Employees: 610
Company Website: https://www.intracellulartherapies.com/
Investor Relations: https://ir.intracellulartherapies.com/
Phone: 16464409333
ITCI FAQ
What is the stock price of ITCI?
The current stock price of ITCI is 126.9 USD.
What is the symbol for INTRA-CELLULAR THERAPIES INC stock?
The exchange symbol of INTRA-CELLULAR THERAPIES INC is ITCI and it is listed on the Nasdaq exchange.
On which exchange is ITCI stock listed?
ITCI stock is listed on the Nasdaq exchange.
Is ITCI a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ITCI, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ITCI.
Does ITCI stock pay dividends?
ITCI does not pay a dividend.
When does ITCI stock report earnings?
ITCI will report earnings on 2025-02-26, after the market close.
What is the Price/Earnings (PE) ratio of ITCI?
ITCI does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.87).
What is the Short Interest ratio of ITCI stock?
The outstanding short interest for ITCI is 1.47% of its float.
ITCI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ITCI. When comparing the yearly performance of all stocks, ITCI is one of the better performing stocks in the market, outperforming 94.05% of all stocks.
ITCI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ITCI. No worries on liquidiy or solvency for ITCI as it has an excellent financial health rating, but there are worries on the profitability.
ITCI Financial Highlights
Over the last trailing twelve months ITCI reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS increased by 45.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.52% | ||
| ROE | -7.54% | ||
| Debt/Equity | 0 |
ITCI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ITCI. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 50.93% and a revenue growth 44.35% for ITCI